Bright Minds Biosciences announced a non-brokered private placement with expected gross proceeds of $35 million. The company's stock is currently trading with a session volume of about 10.6 million.
Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results